2009-08-07 14:07:01 -

NexMed, Inc. (Nasdaq: NEXM), a developer of innovative topical products based on the NexACT ® technology, today announced that management will hold a conference call to discuss 2009 second quarter financial results and ongoing corporate activities, on Tuesday, August 11, 2009 at 10:00 a.m. EDT. The Company will file its Form 10-Q by the end of business on Monday, August 10,

2009.

The call can be accessed in the U.S. by dialing 877-407-9205 and outside of the U.S. by dialing 201-689-8054 and asking the conference operator for the NexMed Conference Call. The teleconference replay is available for one week by dialing in the U.S. 877-660-6853 and outside of the U.S.
by dialing 201-612-7415. Replay pass codes 286 and 330142 are both required for playback. The conference call will also be Webcast live at URL www.investorcalendar.com/IC/CEPage.asp?ID=148473 : .
The Webcast replay will be available for three months.

About NexMed


NexMed’s pipeline includes a late stage terbinafine treatment for onychomycosis, a late stage alprostadil treatment for erectile dysfunction, a P 2 alprostadil treatment for female sexual arousal disorder, and an early stage treatment for psoriasis. For further information about NexMed, go to www.nexmed.com : .

Statements under the Private Securities Litigation Reform Act: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may individually or mutually impact the matters herein described, including, but not limited to entering into development and commercialization agreements and obtaining regulatory approval for its products under development, entering into a strategic transaction for the company, pursuing growth opportunities, and/or other factors, some of which are outside the control of the Company.



Company:NexMed, Inc.Mark Westgate, CFO, 609-371-8123,
ext: 159 mwestgate@nexmed.com : mailto:mwestgate@nexmed.com orInvestor

Relations:Rx Communications Group, LLCPaula Schwartz,

917-322-2216 pschwartz@rxir.com : mailto:pschwartz@rxir.com